Efficacy and Safety of Ranolazine in Patients With Chronic Stable Angina

  title={Efficacy and Safety of Ranolazine in Patients With Chronic Stable Angina},
  author={R. Kloner and M. Hines and S. Geunes-Boyer},
  journal={Postgraduate Medicine},
  pages={43 - 52}
  • R. Kloner, M. Hines, S. Geunes-Boyer
  • Published 2013
  • Medicine
  • Postgraduate Medicine
  • Abstract Chronic stable angina (CSA) impairs patient quality of life, is associated with increased patient mortality, and is a prominent symptom of coronary artery disease (CAD), the latter being prevalent worldwide in patients. Currently, therapeutic options for patients with CSA include β-blockers, calcium channel blockers, nitrates, and ranolazine. Ranolazine is a first-in-class piperazine derivative that inhibits the late inward sodium current in cardiac cells and is considered an effective… CONTINUE READING
    11 Citations
    Effects of ranolazine on left ventricular diastolic and systolic function in patients with chronic coronary disease and stable angina.
    • 6
    • PDF
    Electrocardiogram Changes From Ranolazine or From Takotsubo?
    • L. Littmann
    • Medicine
    • The American journal of medicine
    • 2015
    • 1
    Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure.
    • 3
    • PDF
    Executive Summary of the Guidelines on Stable Coronary Disease
    Guideline for stable coronary artery disease.
    • 43
    • PDF


    Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
    • 494
    • PDF
    Efficacy and Safety of a Metabolic Modulator Drug in Chronic Stable Angina: Review of Evidence from Clinical Trials
    • B. Chaitman
    • Medicine
    • Journal of cardiovascular pharmacology and therapeutics
    • 2004
    • 45